In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11,…
New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including…
Parsippany, NJ – October 18, 2021 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from…
Ferring will present four abstracts at the congress including two oral and two poster presentations Ferring is demonstrating its leadership…
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as…
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021…
Fertility House Calls connects women and couples with personalized fertility care from the comfort of their own home. Service designed…
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up…
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is…
For the first time ever, Ferring and Rebiotix, a Ferring Company, will present landmark Phase 3 efficacy and safety data…